ArticlePeerJ2020
A diverse global fungal library for drug discovery.
Article in PeerJ, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Larvicidal and adulticidal activities of Purpureocillium lilacinum Secondary Metabolites against the Malaria Vector Anopheles gambiae.Research square · 2026Article
- Leucinostatins target Plasmodium mitochondria to block malaria transmission.Parasites & vectors · 2024Article
- Leucinostatins from fungal extracts block malaria transmission to mosquitoes.Parasites & vectors · 2024Article
- Article
- Codeine dysregulates ribosome biogenesis inFuture drug discovery · 2023Article
- Arsinothricin InhibitsMicroorganisms · 2023Article
- Discovery of mosquitocides from fungal extracts through a high-throughput cytotoxicity-screening approach.Parasites & vectors · 2021Article
- Sterigmatocystin LimitsPharmaceuticals (Basel, Switzerland) · 2021Article
- A novel fungal metabolite inhibits Plasmodium falciparum transmission and infection.Parasites & vectors · 2021Article
- Studies of the Parasite-Midgut Interaction RevealFrontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSecondary fungal metabolites are important sources for new drugs against infectious diseases and cancers.
methodsTo obtain a library with enough diversity, we collected about 2,395 soil samples and 2,324 plant samples from 36 regions in Africa, Asia, and North America. The collection areas covered various climate zones in the world. We examined the usability of the global fungal extract library (GFEL) against parasitic malaria transmission, Gram-positive and negative bacterial pathogens, and leukemia cells.
resultsNearly ten thousand fungal strains were isolated. Sequences of nuclear ribosomal internal transcribed spacer (ITS) from 40 randomly selected strains showed that over 80% were unique. Screening GFEL, we found that the fungal extract from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.